ZymoGenetics Furthers Bristol's "Multi-Pronged" Approach To HCV, Sigal Says
R&D President Sigal talks about how the acquisition of ZymoGenetics fits into Bristol's research strategy in his first public comments to investors since March.
R&D President Sigal talks about how the acquisition of ZymoGenetics fits into Bristol's research strategy in his first public comments to investors since March.